Previous Article | Next Article ![]()
Infect Immun, June 1998, p. 2879-2886, Vol. 66, No. 6
OraVax, Inc., Cambridge, Massachusetts 02139
Received 29 October 1997/Returned for modification 16 December
1997/Accepted 12 March 1998
To determine the optimal inductive sites for immunization against
Helicobacter pylori infection, the protective efficacy of recombinant urease (rUre) was assessed for mice given the vaccine by
either the oral (p.o.), intranasal (i.n.), or rectal route. When mice
were immunized with rUre (25 µg p.o. or rectally or 10 µg i.n.)
plus heat-labile toxin from Escherichia coli as the mucosal
adjuvant, all routes afforded protection against challenge with
H. pylori, as indicated by a significant reduction in
gastric urease activity (P < 0.0005) compared to that
of sham-immunized controls. Quantitative H. pylori culture
of stomach tissue demonstrated a >97% reduction in bacterial burden
in mice immunized by all routes (P < 0.05). Induction
of antiurease immunoglobulin A (IgA) levels in gastric luminal
secretions after p.o. immunization was greater than after i.n.
administration (means, 6.0 and 1.02 ng/ml, respectively) and was
dependent upon challenge with H. pylori. However,
immunization by the rectal route resulted in the generation of the
highest levels of gastric antiurease IgA (mean, 40.89 ng/ml), which was
detectable prior to challenge with H. pylori.
Immunohistochemical staining of stomach tissue for cells secreting
urease-specific antibody and CD4+ T cells showed levels of
recruitment to be dependent upon challenge with H. pylori
and equivalent for all routes. These results identify both the rectum
and nasal passages as suitable inductive sites for urease immunization.
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Rectal and Intranasal Immunizations with
Recombinant Urease Induce Distinct Local and Serum Immune Responses in
Mice and Protect against Helicobacter pylori
Infection
*
Corresponding author. Mailing address: OraVax, Inc., 38 Sidney St., Cambridge, MA 02139. Phone: (617) 494-1339. Fax: (617) 494-1741. E-mail: hkleanth{at}oravax.com.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|